Nephrocare Health Services Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹303 Cr +23.2% YoYSee revenue, profit and what management said. You are viewing Q4 FY26.
NH

Nephrocare Health Services Ltd

Q4 FY26Healthcare Services

Nephrocare Health Services Q4 FY26 earnings call: Revenue & Margins

Q4 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹266Cr
+21.5% YoY
+2.3% QoQ
Net profit
₹30Cr
+20% YoY
−6.2% QoQ
Margin
19%
−4 pp YoY
−4 pp QoQ

What the Q4 FY26 call signalled

2 of 3 strong

RevenueGood growth
MarginMargins steady
CapexCapex planned
Price₹694
Market cap₹7.0K Cr
P/E82.3

The short version

FY26 revenue grew by 32.2% YoY to INR 998.8 crores, driven by higher treatment volumes, clinic utilization, and increased revenue per treatment (RPT). NephroPlus expects a medium-term CAGR growth of 15% to 20% over the next 3-4 years driven by three growth levers: same-clinic growth, new clinic rollout in existing geographies, and new geography/large acquisitions/PPPs.

From Nephrocare Health Services Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

Good growth
  • FY26 revenue grew by 32.2% YoY to INR 998.8 crores, driven by higher treatment volumes, clinic utilization, and increased revenue per treatment (RPT).
  • Treatment volumes increased 16.6% YoY; active guests up 11.8%.
  • RPT rose 13.3%, boosted by international market mix increase (32% to 42%), favorable forex, and a 58% price hike in the Philippines.
  • India plans to add 40-50 new clinics annually; Philippines targeting 12-15 clinics/year.
  • Clinic expansions focus on treatment volume growth, as per-machine capacity is fixed; new clinics needed for volume increase.
  • Price hikes are infrequent and stepwise; no significant increases expected next year; growth primarily volume-driven.

2 more points from Nephrocare Health Services Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Nephrocare Health Services Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned
  • FY 2026 capex was INR 165 crores, split evenly between India, Philippines, and a bit in Uzbekistan.
  • Capex per bed: India ~ INR 10-11 lakhs, Philippines ~ INR 40-45 lakhs.
  • Payback periods: India ~3.5-4 years, Philippines ~1-1.5 years.
  • Planned clinic additions: India 40-50 new clinics/year, Philippines 12-15 new clinics/year (excluding large PPPs or big acquisitions).
  • Future investments include expanding Philippines support areas like supply chain management and business development.
  • Repair and maintenance expenses now flow through operating expenses due to accounting changes.
  • Exploring Public-Private Partnership (PPP) models in Philippines and India as a strategic growth lever.

2 more points from Nephrocare Health Services Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Healthcare Services

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
Rev 1Mar 3
3
Rev 2Mar 1
4
Rev 2Mar 1
5
Rev 2Mar 1
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Nephrocare Health Services Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Relevant insights include: - Saudi Arabia tender market: The company is in the investment phase; a new tender was released about a month ago and is at the Expression of Interest (EOI) stage. Final visibility on clinic count or order conversion expected in a few quarters. - PPP contracts: For example, the Uttarakhand PPP contract is under renewal with tendering ongoing; resolution expected in 2-4 months, though delays possible. - Growth levers: Expansion includes new clinics (40-50 in India; 12-15 in Philippines), excluding large M&A or PPP contracts which are unpredictable and not currently factored into AOP.

Nephrocare Health Services Ltd — Quarterly revenue & net profit

Revenue Net profit Net loss
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Nephrocare Health Services Ltd Q4 FY26 results — key figures

Nephrocare Health Services Ltd Q4 FY26 reported results vs Q4 FY25, ₹ crore
₹ CrQ4 FY26Q4 FY25YoYQ3 FY26QoQ
Revenue266219+21.5%260+2.3%
Operating profit (EBITDA)51510%61-16.4%
Operating margin19%23%-4 pp23%-4 pp
Profit before tax3330+10%36-8.3%
Net profit (PAT)3025+20%32-6.2%
EPS (₹)3.0323.91-87.3%3.21-5.6%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹303 Cr, net profit ₹34 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

What Nephrocare Health Services's management said in earlier quarters

Others in Healthcare Services this season

  • Suven Life Sciences (Q4 FY26)

    The provided pages of the investor presentation do not report any revenue, sales, or volume figures for the quarter. Key investor presentation takeaways from Su

  • Invicta Diagnostic (Q4 FY26)

    Invicta Diagnostic Limited is deploying IPO funds (INR 21 crores raised) primarily towards: . Key concall takeaways from Invicta Diagnostic's Q4 FY26 earnings…

  • KMC Speciality (Q4 FY26)

    Q4 FY’26 Revenue from Operations: INR 82.3 Cr, up 35.0% YoY from INR 60.9 Cr in Q4 FY’25 (Page 20) . Key concall takeaways from KMC Speciality Hospitals…

  • Star Imaging (Q4 FY26)

    Capex planned for FY27 is around INR 20 to 25 crores, mainly towards new centres and equipment. Key concall takeaways from Star Imaging's Q4 FY26 earnings call…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Nephrocare Health Services Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Nephrocare Health Services Ltd Q4 FY26 results?

FY26 revenue grew by 32.2% YoY to INR 998.8 crores, driven by higher treatment volumes, clinic utilization, and increased revenue per treatment (RPT). NephroPlus expects a medium-term CAGR growth of 15% to 20% over the next 3-4 years driven by three growth levers: same-clinic growth, new clinic rollout in existing geographies, and new geography/large acquisitions/PPPs.

What is Nephrocare Health Services Ltd share price analysis?

Nephrocare Health Services Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 82.3 with a market cap of ₹7,006 Cr. Investors should review the full earnings analysis for detailed insights.

Is Nephrocare Health Services Ltd planning capital expenditure?

FY 2026 capex was INR 165 crores, split evenly between India, Philippines, and a bit in Uzbekistan.

Keep Nephrocare Health Services Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.